NCT03799848COMPLETEDanonymous

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Vadadustat

Indication / condition

AI-normalized

Hepatic Impairment

Intervention

Source record

Vadadustat

Related intelligence directories

Indication directory: Hepatic Impairment Modality directory: small molecule Target directory: Vadadustat

Source & freshness

Source record

NCT ID

NCT03799848

Original source

ClinicalTrials.gov

Source last updated

Mar 22, 2019

Ingested at

Jun 03, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03799848

Title

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 1

Condition raw

Hepatic Impairment

Condition normalized

Hepatic Impairment

Modality raw

Hepatic Impairment

Modality normalized

small molecule

Target raw

Vadadustat

Target normalized

Vadadustat

Interventions

Vadadustat

Public preview

Source record

This Phase 1 clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetic profile of a single oral dose of vadadustat in subjects with varying degrees of hepatic function. The study aimed to assess safety and tolerability in a controlled setting.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 1, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03799848

Status

COMPLETED

Phase

Phase 1

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 22, 2019

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03799848

Indication

Hepatic Impairment

Modality

small molecule

Target

Vadadustat

Intervention

Vadadustat

Source record